According to patients’ genetic background [30, 31] the presence of various comorbidities, and body weight [14], clinicians might be required to determine whether to continue TDF or switch to TAF to prevent the progression to renal tubular dysfunction or metabolic disorders, using biomarkers such as urinary L-FABP and NTx. This evidence concerns the gene FABP1 and Other metabolic disease.